SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-074215
Filing Date
2022-11-21
Accepted
2022-11-21 16:06:12
Documents
93
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0922_immucellcorp.htm   iXBRL 10-Q 1191480
2 THIRD AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT BETWEEN THE COMPANY f10q0922ex10_immucellcorp.htm EX-10 10543
3 CERTIFICATION f10q0922ex31_immucellcorp.htm EX-31 9958
4 CERTIFICATION f10q0922ex32_immucellcorp.htm EX-32 5460
  Complete submission text file 0001213900-22-074215.txt   7128095

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE iccc-20220930.xsd EX-101.SCH 93287
6 XBRL CALCULATION FILE iccc-20220930_cal.xml EX-101.CAL 37993
7 XBRL DEFINITION FILE iccc-20220930_def.xml EX-101.DEF 307606
8 XBRL LABEL FILE iccc-20220930_lab.xml EX-101.LAB 647694
9 XBRL PRESENTATION FILE iccc-20220930_pre.xml EX-101.PRE 331401
87 EXTRACTED XBRL INSTANCE DOCUMENT f10q0922_immucellcorp_htm.xml XML 1136762
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

IRS No.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12934 | Film No.: 221405797
SIC: 2835 In Vitro & In Vivo Diagnostic Substances